Plain-English translation of NCT07685405 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Researchers are studying blood samples from patients with Ewing sarcoma to find special markers—tiny particles in the blood called extracellular vesicles—that could help doctors develop better treatments. By comparing blood from patients with Ewing sarcoma to blood from healthy people, the study aims to understand what makes these markers unique to the disease. This information could eventually lead to new ways to diagnose and treat Ewing sarcoma.
Currently, doctors need better tools to monitor Ewing sarcoma and develop new therapies. By identifying these blood markers, researchers hope to create faster, less invasive ways to track the disease and test new treatments in the future.
You likely qualify if…
You likely don't qualify if…
If you qualify, you will be asked to donate a blood sample, which typically takes just a few minutes. The researchers will then analyze your blood to look for the special markers they're studying. There are no ongoing visits or long-term commitments—this is a single blood draw study designed to be quick and straightforward.
AI-generated summary from trial data · Aug 22, 2026 · Not medical advice
Italy
Enrollment target
~16 participants
Started
April 2026
Primary completion
April 2028
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Katia Scotlandi, MSc
Istituto Ortopedico Rizzoli
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.